- Home
- VTLE vs COLL Comparison
VTLE vs COLL Comparison
Compare VTLE & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTLE
- COLL
- Stock Information
- Founded
- VTLE 2006
- COLL 2002
- Country
- VTLE United States
- COLL United States
- Employees
- VTLE N/A
- COLL N/A
- Industry
- VTLE
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- VTLE
- COLL Health Care
- Exchange
- VTLE Nasdaq
- COLL Nasdaq
- Market Cap
- VTLE 1.2B
- COLL 1.1B
- IPO Year
- VTLE 2011
- COLL 2015
- Fundamental
- Price
- VTLE $35.90
- COLL $33.35
- Analyst Decision
- VTLE Hold
- COLL Strong Buy
- Analyst Count
- VTLE 10
- COLL 5
- Target Price
- VTLE $44.63
- COLL $43.80
- AVG Volume (30 Days)
- VTLE 837.2K
- COLL 486.5K
- Earning Date
- VTLE 02-19-2025
- COLL 02-20-2025
- Dividend Yield
- VTLE N/A
- COLL N/A
- EPS Growth
- VTLE N/A
- COLL 757.11
- EPS
- VTLE 13.16
- COLL 2.16
- Revenue
- VTLE $1,862,465,000.00
- COLL $599,245,000.00
- Revenue This Year
- VTLE $29.36
- COLL $13.20
- Revenue Next Year
- VTLE $7.49
- COLL $17.63
- P/E Ratio
- VTLE $2.73
- COLL $15.42
- Revenue Growth
- VTLE 26.94
- COLL 9.62
- 52 Week Low
- VTLE $25.85
- COLL $28.39
- 52 Week High
- VTLE $58.30
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- VTLE 70.15
- COLL 62.31
- Support Level
- VTLE $27.93
- COLL $32.29
- Resistance Level
- VTLE $36.72
- COLL $33.99
- Average True Range (ATR)
- VTLE 1.01
- COLL 1.29
- MACD
- VTLE 0.48
- COLL 0.51
- Stochastic Oscillator
- VTLE 89.22
- COLL 87.40
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.